Ananda Pharma CEO Melissa Sturgess joined Steve Darling from Proactive to announce the company’s shares have begun trading on the OTCQB market in the United States, using the ticker ANANF. This a strategic move that expands Ananda’s visibility and access to U.S. investors. The UK-based biopharmaceutical company is focused on developing regulatory-approved cannabinoid medicines for complex and chronic medical conditions.
Sturgess emphasized the significance of entering the U.S. market, not only from a capital markets perspective but also as a key future territory for Ananda’s clinical and commercial ambitions. She also highlighted recent progress in the company’s clinical development pipeline, particularly around its lead investigational drug candidate, MRX1.
Ananda recently received approval from the Alfred Hospital Human Research Ethics Committee in Australia to initiate a Phase 1 pharmacokinetic study of MRX1. The study will evaluate the safety, tolerability, and pharmacokinetics of two dose levels of the CBD-based drug in a cohort of 20 healthy adult volunteers—10 biological males and 10 biological females—to address known sex differences in CBD metabolism.
MRX1 is a high-purity, pharmaceutical-grade cannabidiol (CBD) formulation developed under rigorous quality standards to ensure consistency, safety, and clinical reliability. It is intended for the treatment of chronic inflammatory pain conditions, where current treatment options often fall short in efficacy or come with undesirable side effects.
Sturgess noted that this ethics approval marks a critical milestone in the company’s journey toward regulatory approval and commercial readiness. The trial is expected to generate key safety and dosing data to support future Phase 2 studies targeting patients with unmet needs in chronic pain management.
#proactiveinvestors #aqse #ana #cbd #otcqb #MRX1 #CBDDrugDevelopment #CannabinoidTherapy #ClinicalTrials #FDAApproval #PharmaNews #BiotechStocks #OTCQB #GWPharma #CBDMedicine #ChronicPainTreatment #EndometriosisResearch #NeuropathicPain #ProactiveInvestors